These as well as other objects and advantages of this invention, will be more completely understood and appreciated by referring to the following more detailed description of the presently preferred exemplary embodiments of the invention in conjunction with the accompanying drawings of which:
Referring to
Before inflation, a retractable delivery sheath 110 can be inserted into the intrauterine cavity 111 to provide a path for insertion of the cryoballoon 102. Cryoballoon system 100 can be provided with a handle 112 that rests against retractable delivery sheath 110 upon insertion to ensure that cryoballoon 102 is neither over inserted nor under inserted with respect to the intrauterine cavity. Following insertion, cryoballoon 102 can be inflated with the chilled and/or pressurized fluid using the inflation bulb 104 as described above to conform to the intrauterine cavity. The pressurized and/or chilled fluid within cryoballoon 102 provides numbing and promotes blood coagulation of damaged tissue 115 and/or blood vessels that are bleeding as a result of PPH. Inflation bulb 104 can also be provided with a standard release valve to deflate the cryoballoon 102 and allow its removal subsequent to treatment. In some embodiments, cryoballoon 102 can comprise a biodegradable, bioerodeable or other long term bio-compatible material such that the cryoballoon 102 can remain within the intrauterine cavity 111 for an extended period of time upon insertion.
In some representative embodiments, an exterior portion of cryoballoon 102 can be coated with various treatment agents 113 to improve the ease and effectiveness of the treatment. In one representative embodiment, treatment agent 113 can comprise a coagulation agent. Alternatively, treatment agent 113 can comprise a contraction stimulating agent such as, for example, oxytocic drugs including oxytocin, ergonovine, methylergonovine, carboprost and misoprostoal. In yet another embodiment, treatment agent 113 can comprise a numbing agent. Treatment agent 113 can further comprise a cleansing agent such as, for example, an antiseptic. Finally, treatment agent 113 can further comprise a suitable antibiotic.
Referring now to
Cryoballoon 202 can be situated over a distal end 207 of a fluid channel 212. A proximal end 209 of fluid channel 212 is operably connected to canister 204 such that a fluid pathway 211 is defined between the cryoballoon 202 and the canister 204. Upon insertion of the cryoballoon 202 into the intrauterine cavity, a valve assembly 208 can be turned to release the fluid 206 through a check valve 210, or other one way valve, and into the channel 212. Fluid 206 flows through the fluid pathway 211 and is released into the cryoballoon 202 through a plurality of dispensing apertures or vent holes 214 located at distal end 207 of fluid channel 212. Cryoballoon 202 can optionally be inserted with the aid of the retractable delivery sheath 110, as described above. A vent line 216 can be connected to cryoballoon system 200 to ensure that the cryoballoon 202 is not over inflated. In some representative embodiments, cryoballoon system 200 can be provided with an auto-pressure sensing means to ensure the cryoballoon 202 is not over inflated, and in some situations to automatically vent cryoballoon 202 through vent line 216.
Once the cryoballoon 202 is inflated, the connection with canister 204 can be broken at fluid channel 212 and the canister 204 can be discarded. The check valve 210 can remain within the fluid channel 212 to ensure that the cryoballoon 202 remains inflated and that fluid is not released through fluid channel 212. Pressure can be released from the cryoballoon 202 so that it can be deflated and removed by squeezing channel 212 to allow fluid 206 to flow past the check valve 210.
Cryoballoon 202 can additionally be coated on an exterior portion of the cryoballoon 202 with treatment agent 113 to further assist in treatment of damaged tissue 115. Similarly to cryoballoon 102, cryoballoon 202 can comprise a biodegradable, bioerodeable or bio-compatible material such that the cryoballoon 202 can remain in the intrauterine cavity 111 for an extended period of time subsequent to insertion.
Referring to
A representative cryosurgical system that can be used with the embodiment of the present invention depicted in
To utilize cryoballoon system 300 with cryosurgical system 310, a cryoballoon 300 can be attached and sealed to a cryoprobe tip portion 304 of an existing cryoprobe 314. Alternatively, cryoprobe 314 may be specially formed with an integral cryoballoon 300. When the chilled fluid flows into cryoprobe tip portion 304, it flows through apertures 306 and fills cryoballoon 302, providing numbing and imparting pressure onto the intrauterine cavity. Cryoballoon system 300 can also be provided with a tube to allow the fluid to be drained out of the intrauterine cavity after treatment. Alternatively, the fluid can be recirculated back to the control console 312 to be re-cooled and/or re-pressurized for a subsequent procedure.
Cryoballoon 302 can be coated with treatment agent 113 to promote healing and treatment of damaged tissue 115. Cryoballoon 302 can comprise a biodegradable, bioerodeable or bio-compatible material such that the cryoballoon 302 can remain in the intrauterine cavity 111 for an extended period of time subsequent to insertion.
While the invention has been described in connection with what is presently considered to be the most practical and preferred embodiments, it will be apparent to those of ordinary skill in the art that the invention is not to be limited to the disclosed embodiments. It will be readily apparent to those of ordinary skill in the art that many modifications and equivalent arrangements can be made thereof without departing from the spirit and scope of the present disclosure, such scope to be accorded the broadest interpretation of the appended claims so as to encompass all equivalent structures and products.
The present application claims priority to U.S. Provisional Application No. 60/820,520, filed Jul. 27, 2006 and entitled “CRYOBALLOON TREATMENT FOR POSTPARTUM HEMORRHAGE”, which is herein incorporated by reference in its entirety.
Number | Date | Country | |
---|---|---|---|
60820520 | Jul 2006 | US |